Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and <i>in vivo</i> study

Madane, Rohini G; Mahajan, Hitendra S.

doi:10.3109/10717544.2014.975382

Cited by 192 publications

(101 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Testing in Wistar rats showed that maximum concentration was reached after approximately 3 hours, and delivery to brain tissues was greater with the lipid carrier than the plain drug suspension (86 and 54 ng/g, resp.) [79]. …”

Section: Delivery Mechanismsmentioning

confidence: 99%

Therapeutic Potential of Curcumin for the Treatment of Brain Tumors

Klinger

Mittal

2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Brain malignancies currently carry a poor prognosis despite the current multimodal standard of care that includes surgical resection and adjuvant chemotherapy and radiation. As new therapies are desperately needed, naturally occurring chemical compounds have been studied for their potential chemotherapeutic benefits and low toxicity profile. Curcumin, found in the rhizome of turmeric, has extensive therapeutic promise via its antioxidant, anti-inflammatory, and antiproliferative properties. Preclinical in vitro and in vivo data have shown it to be an effective treatment for brain tumors including glioblastoma multiforme. These effects are potentiated by curcumin's ability to induce G2/M cell cycle arrest, activation of apoptotic pathways, induction of autophagy, disruption of molecular signaling, inhibition of invasion, and metastasis and by increasing the efficacy of existing chemotherapeutics. Further, clinical data suggest that it has low toxicity in humans even at large doses. Curcumin is a promising nutraceutical compound that should be evaluated in clinical trials for the treatment of human brain tumors.

show abstract

Section: Delivery Mechanismsmentioning

confidence: 99%

Therapeutic Potential of Curcumin for the Treatment of Brain Tumors

Klinger

Mittal

2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Nanostructured lipid carriers (NLCs), the latest generation of lipid-based nanoparticles, were introduced in the late 1990s. NLCs were composed of a binary mixture of a solid lipid and a liquid lipid (Madane & Mahajan, 2014). Given their structure and characteristics, NLCs can be considered as preferable nanovectors to load poor soluble drugs; increase drug loading and longer assure molecule stability (Shidhaye et al, 2008;Han et al, 2015;Shao et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy

et al. 2015

View full text Add to dashboard Cite

Purpose: Gastric carcinoma is one of the most common cancers and the second most frequent cause of cancer-related deaths. The aim of this study was to prepare and characterize etoposide-loaded nanostructured lipid carriers (ETP-NLCs) and evaluate their antitumor activity in vitro and in vivo. Methods: Novel ETP-NLCs were constructed. The physicochemical properties of the ETP-NLCs were investigated by particle-size analysis, zeta potential measurement, drug loading, drug entrapment efficiency, stability and in vitro drug release behavior. In vitro cytotoxicity against human gastric cancer cells (SGC7901 cells) was investigated, and in vivo antitumor of NLCs was evaluated on mice bearing SGC7901 cells xenografts. Results: ETP-NLCs have a narrow size distribution at 91 nm, a zeta potential value of +23.1 mV, high drug entrapment efficiency of 78%. The drug release of ETP-NLCs exhibited a sustained behavior, which made it an ideal vehicle for drug delivery. Furthermore, ETP-NLCs could significantly enhance in vitro cytotoxicity and in vivo antitumor effect against SGC7901 cells and gastric cancer animal model compared to the free drug. Conclusion:The results demonstrated that the NLCs might be a promising nanomedicine for the treatment of gastric carcinoma. KeywordsGastric cancer therapy, in vivo drug delivery, in vitro cytotoxicity, nanostructured lipid carriers History

show abstract

“…There are many nanodelivery systems reported in recent years, including PLGA (Mayol et al, 2015), polymer (1) denotes lower concentration of 10 mg/mL, (2) denotes higher concentration of 20 mg/mL, and doses are based on the amount of CUR. (Alizadeh et al, 2015), SLNs and NLCs (Madane & Mahajan, 2014). Both SLNs and NLCs are reported as an ideal nanocarrier for helping passing through the BBB, and NLC appears to be superior to SLN with smaller particle size and higher drug loading (Gokce et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo

et al. 2015

View full text Add to dashboard Cite

Brain cancer is a kind of tough carcinoma because the blood-brain barrier (BBB) remains a formidable obstacle in medicine. Curcumin (Cur) was determined to have anticancer potency on several kinds of carcinoma. However, its medical application was limited because of its poor bioavailability, unsatisfying dispersity and rapid metabolism in vivo. In this study, Cur was delivered by nanostructured lipid carriers (NLCs) for brain cancer treatment. The physiochemical characters of NLC-Cur were detected by using high-performance liquid chromatography, Transmission electron microscopy and photon correlation spectrum analyses. The cellular uptake and the anticancer efficiency were determined both in vitro and in vivo by flow cytometry detection, MTT assay, AO/EB, Annexin-V/PI, DCFDA and tumor-bearing mice. NLC-Cur was synthesized by using sol-gel method and with the size around 100 nm. After loaded in NLC, the IC 50 of NLC-Cur was 20 mg/mL, only one-fourth of the plain drug. The plasmid concentration of Cur was highly increased (6.4-folds) in mice via intraperitoneally after loaded with NLC. Furthermore, NLC-Cur enhanced the targeting effect of Cur to brain and tumor, which finally increased the inhibition efficiency of Cur from 19.5% to 82.3%. The FITC analysis confirmed that the inhibition effect mostly came from apoptosis, but not necrosis. The time depending cellular uptake, reactive oxygen species production, markedly increased bio-availability and tumor targeting effect played an important role in the efficacy of NLC-Cur. Our work indicated the medical application of NLC-Cur on brain cancer treatment, and also provided a novel method for new anticancer agents' development.

show abstract

Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study

Cited by 192 publications

References 23 publications

Therapeutic Potential of Curcumin for the Treatment of Brain Tumors

Therapeutic Potential of Curcumin for the Treatment of Brain Tumors

Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy

Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo

Contact Info

Product

Resources

About